Welcome to our dedicated news page for FSD Pharma Class B Subordinate Voting Shares (Ticker: HUGE), a resource for investors and traders seeking the latest updates and insights on FSD Pharma Class B Subordinate Voting Shares.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FSD Pharma Class B Subordinate Voting Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FSD Pharma Class B Subordinate Voting Shares's position in the market.
Rhea-AI Summary
FSD Pharma Inc. (HUGE) obtained a final order from the Ontario Superior Court of Justice approving the statutory plan of arrangement to distribute Celly Nutrition Corp. shares to FSD Pharma Securityholders. The special resolution to authorize the Arrangement was approved on November 20, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
-
Rhea-AI Summary
Goldman Small Cap Research has published a new research report on FSD Pharma, Inc. (HUGE) highlighting its innovative biopharmaceutical products, including a patented compound for multiple sclerosis and a functional beverage for relieving the effects of alcohol consumption. The report includes a price target and emphasizes the company's potential for substantial growth and market penetration. FSD Pharma is also set to go ex-dividend on November 27, 2023, rewarding shareholders with stock in the firm launching the UNBUZZD product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
-
Rhea-AI Summary
FSD Pharma Inc. (HUGE) has announced the approval of a plan of arrangement under which common shares in the capital of Celly Nutrition Corp. will be distributed to FSD Pharma Securityholders. The Celly Nu Shares will be distributed on November 29, 2023, subject to certain restrictions on transfer. The Arrangement is expected to close at or around the end of November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.3%
Tags
Rhea-AI Summary
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) Announces Distribution Date for Contemplated Plan of Arrangement. The company will distribute Celly Nutrition Corp. shares to FSD Pharma Securityholders, subject to closing conditions, with an ex-dividend date of November 27, 2023. The expected distribution is approximately 45,694,621 Celly Nu Shares to FSD Pharma Securityholders and 154,305,379 Celly Nu Shares retained by the Company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
-
Rhea-AI Summary
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) has provided additional disclosure through a Supplement to its Management Information Circular, regarding restrictions on resale of Celly Nu Shares distributed to FSD Pharma Securityholders. The Supplement can be accessed online, and proxies for the Meeting will be accepted until November 17, 2023, 5:00 p.m. (Toronto time).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.42%
Tags
-
Rhea-AI Summary
FSD Pharma Inc. will be announcing the record date for the Company's special dividend of shares of Celly Nutrition Corp, the holder of exclusive rights to FSD Pharma's revolutionary recreational alcohol misuse technology. The dividend ratio is 1:1, meaning that for every FSD Pharma share or warrant held by an investor, one Celly Nu Share will be delivered to that investor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
Rhea-AI Summary
FSD Pharma has filed a preliminary short form base shelf prospectus to replace its expired base shelf prospectus. The new prospectus will allow the company to offer, issue, and sell securities for up to an aggregate offering price of USD$50 million during the 25-month effective period. The company may also use the prospectus for an 'at-the-market distribution' through the Canadian Securities Exchange.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
-
Rhea-AI Summary
FSD Pharma files management information circular for special meeting to approve plan of arrangement with Celly Nutrition Corp.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
-
Rhea-AI Summary
FSD Pharma and Celly Nutrition Corp. enter into an agreement for the distribution of FSD Pharma's shareholdings of Celly Nu to certain securityholders of FSD Pharma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
Rhea-AI Summary
The Ontario Superior Court of Justice has dismissed the motion to set aside the arbitration award to FSD Pharma filed by Dr. Raza Bokhari, the former CEO of FSD Pharma and current CEO of Medicus Pharma. FSD Pharma has been awarded approximately CDN$2.81 million in costs of arbitration. The Court also ordered Dr. Bokhari to pay FSD Pharma $175,000 to cover its legal costs for his failed set aside motion. FSD Pharma will vigorously pursue to collect the monetary awards and all accruing interest at a rate of 6%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
FSD Pharma Inc. Class B Subordinate Voting Shares
Nasdaq:HUGE
HUGE Rankings
HUGE Stock Data
15.18M
34.34M
17.37%
2.53%
0.82%
Medicinal and Botanical Manufacturing
Manufacturing
United States of America
Toronto
About HUGE
fsd pharma inc., through its subsidiary, fv pharma inc., produces medical cannabis in canada. the company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, gi tract, and musculoskeletal system, such as chronic pain. fsd pharma inc. has strategic alliance agreements with scicann therapeutics inc., canntab therapeutics, and solarvest bioenergy inc. the company was founded in 1998 and is headquartered in toronto, canada.